RxDoctor Payments Data

Nicholas Santalucia

Psychiatric/Mental Health · Richmond, VANPI 1255065488

Payments from drug & device makers

$3,995in general payments, 2019–2025

Across 145 payments — averaging $27.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$777
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$724
  • Teva Pharmaceuticals USA, Inc.$549
  • Otsuka America Pharmaceutical, Inc.$411
  • Vanda Pharmaceuticals Inc.$374
  • AbbVie$327
  • plus $832 from 6 others

What the payments were for

  • Food & beverage$3,83596%
  • Education$1604%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,995 in reported general payments places this provider in the 85th percentile of 1,003 psychiatric/mental health providers in Virginia.

See all psychiatric/mental health providers in Virginia

Medicare billing

Part B allowed, 2024
$10,478
Medicare patients
19
Services billed
116

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CaplytaLumateperone Tosylate17$27,784
Aripiprazole46$4,963
Vilazodone Hcl11$1,221
Fluphenazine Hcl19$683
Methylphenidate Hcl27$362
Trazodone Hcl73$361
Risperidone13$235
Buspirone Hcl21$187
Bupropion XlBupropion Hcl15$169
Lamotrigine31$129
Fluoxetine Hcl29$128
Clonazepam40$121
Escitalopram Oxalate19$120
Lorazepam14$118
Mirtazapine22$80

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$724$27,78417 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,003 psychiatric/mental health providers in Virginia.

Other psychiatric/mental health in Richmond

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →